Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 18 of the 60 sources its claims cite were checked for support.
Abstract
Background: Tapering and discontinuing antidepressants are important aspects of the management of patients with depression and should therefore be considered in clinical practice guidelines. Objectives: We aimed to assess the extent and content, and appraise the quality, of guidance on tapering and discontinuing antidepressants in major clinical practice guidelines on depression. Methods: Systematic review of clinical practice guidelines on depression issued by national health authorities and major national or international professional organisations in the United Kingdom, the United States, Canada, Australia, Singapore, Ireland and New Zealand (PROSPERO CRD42020220682). We searched PubMed, 14 guideline registries and the websites of relevant organisations (last search 25 May 2021). The clinical practice guidelines were assessed for recommendations and information relevant to tapering and discontinuing antidepressants. The quality of the clinical practice guidelines as they pertained to tapering and discontinuation was assessed using the AGREE II tool. Results: Of the 21 included clinical practice guidelines, 15 (71%) recommended that antidepressants are tapered gradually or slowly, but none provided guidance on dose reductions, how to distinguish withdrawal symptoms from relapse or how to manage withdrawal symptoms. Psychological challenges were not addressed in any clinical practice guideline, and the treatment algorithms and flow charts did not include discontinuation. The quality of the clinical practice guidelines was overall low. Conclusion: Current major clinical practice guidelines provide little support for clinicians wishing to help patients discontinue or taper antidepressants in terms of mitigating and managing withdrawal symptoms. Patients who have deteriorated upon following current guidance on tapering and discontinuing antidepressants thus cannot be concluded to have experienced a relapse. Better guidance requires better randomised trials investigating interventions for discontinuing or tapering antidepressants.
Overview
CoChat Summary
TL;DR
This systematic review of 21 major depression clinical practice guidelines found that most recommend gradual or slow antidepressant tapering, but provide little concrete guidance on dose reduction, withdrawal management, or distinguishing withdrawal from relapse. Guideline quality on tapering and discontinuation was overall low, and the authors conclude better guidance requires better randomised trials.
Key findings
- Of 21 included guidelines, 15 (71%) recommended gradual or slow tapering, but none recommended hyperbolic tapering (0%); only 2 (10%) alluded to a specific dose-reduction regimen.
- Withdrawal symptoms were mentioned as a possible harm in 15 (71%) guidelines and relapse/recurrence in 14 (67%), but only 4 (19%) noted the symptomatic overlap or risk of misinterpreting withdrawal as relapse.
- Psychological challenges, potential benefits of coming off antidepressants, and peer-support measures were not mentioned in any guideline (0% each).
- AGREE II overall quality scores for tapering/discontinuation guidance ranged from 8% to 33% (mean 17%, SD 8%), and no guideline reached the predefined >70% threshold for high quality.
Methods
- Systematic review of clinical practice guidelines on depression issued by national health authorities and major national or international professional organisations in the UK, US, Canada, Australia, Singapore, Ireland, and New Zealand (PROSPERO CRD42020220682).
- Searched PubMed, 14 guideline registries, relevant organisation websites, Google top 100 hits, and reference lists; last search 25 May 2021. Included 21 unique guidelines (reported in 26 records), published 1998–2020.
- Two researchers independently extracted data on tapering/discontinuation guidance and assessed quality using AGREE II, focusing items specifically on tapering and discontinuation; results were summarised as proportions and mean domain scores.
Limitations
- Stated by the authors: only English-language guidelines were included, so guidelines from non-English-speaking countries may have been missed; AGREE II has no validated high/low quality threshold and the cutoff used may be considered conservative; categorisation and quality appraisal involved subjective judgements.
- Evident from the text: the AGREE II appraisal was specific to tapering and discontinuation issues rather than an assessment of the guidelines in their totality, and the review evaluates guideline content rather than patient outcomes from tapering interventions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
10 Valid · 0 Not valid · 19 Not checked · 77 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“About half of the patients on antidepressants who try to discontinue or reduce the dose experience withdrawal symptoms”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Introduction
What the sources say
- Supportedcites [4] Davies J Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
The Abstract states that 56% of people attempting to come off antidepressants experience withdrawal effects, and §3.2 reports a weighted incidence of 55.7%. Section 3.2 also includes patients who tapered their dose, so the claim’s reference to discontinuing or reducing the dose is supported. (LLM, conf=0.93)
- Partly supportedcites [5] Lerner A Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 2019; 1: fcz025. PMC7425303 32954266 sourceExperimental — accuracy not yet measured
Part II, under “Antidepressant SSRIs and SNRIs withdrawal syndrome” (page unavailable), describes withdrawal symptoms; its discussion of terminology also says withdrawal can occur when medication is decreased. The paper does not give a figure showing that about half of patients attempting to discontinue or reduce antidepressants experience symptoms (searched: “half of patients” and “50%”). (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“half of the patients who experience them rate the symptoms as severe”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Introduction
What the sources say
- Partly supportedcites [4] Davies J Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 sourceExperimental — accuracy not yet measured
The Severity section (3.3) reports that four independently funded surveys found 'nearly a half' of people who experienced withdrawal effects chose the most extreme severity option, with individual rates of 43%-51% and a weighted average of 45.7% (1157/2529); the Discussion restates this as 'nearly half (46%) as severe'. So the direction and population of the claim are supported, but the source deliberately says 'nearly half', not half — the citing sentence rounds the magnitude up and drops the authors' hedge. Also note the figure comes from self-report surveys of real-world antidepressant users (an included outlier drug-company trial with clinician-rated severity was excluded; including it would lower the average to 43.9%), rather than from patient/clinical-sample data as 'patients' implies. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The incidence and severity of withdrawal symptoms may depend on how the antidepressant is tapered”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Introduction
What the sources say
- Supportedcites [12] Horowitz MA Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 source
The Abstract (p.1) states directly that SSRI withdrawal 'incidence and severity appears to be influenced by half-life and receptor affinities, duration and dose of usage, as well as method of tapering, and individual patient characteristics', matching the claim's hedged 'may depend'. The 'Pharmacological characteristics of SSRI withdrawal' and 'Pharmacological principles to taper SSRIs' sections (pp. 3-4) reinforce that tapering method affects withdrawal, citing randomised tapering studies (para 8 of the Abstract section) showing slower, longer tapers lower incidence and severity. (LLM, conf=0.90)
- Not checked yetcites [13] van Geffen EC Hugtenburg JG Heerdink ER, et al Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005; 61: 303– 307. 15906018 source
- Not checked yetcites [14] Murata Y Kobayashi D Imuta N, et al Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol 2010; 30: 11– 17. 20075642 source
- Not checked yetcites [15] Himei A Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006; 20: 665– 672. 16863271 source
- Not checked yetcites [16] Ruhe HG Horikx A van Avendonk MJP, et al Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 561– 562. 31230677 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, preliminary data from non-randomised trials suggest that hyperbolic tapering through tapering strips may reduce the incidence of withdrawal symptoms.”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Introduction
What the sources say
- Partly supportedcites [17] Groot PC van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1-5 years. Ther Adv Psychopharmacol 2020; 10: 2045125320954609. PMC7476339 32953040 sourceExperimental — accuracy not yet measured
The Introduction identifies taperingstrips as a means of hyperbolic dose reduction, and the Discussion (Findings) reports fewer withdrawal symptoms with taperingstrips than in previous attempts without them (median 1 versus 3). This supports the tentative claim of reduced withdrawal symptoms. However, the Methods describe a retrospective questionnaire rather than a trial, and the comparison measures symptom counts, not the incidence of withdrawal among patients. (LLM, conf=0.82)
- Partly supportedcites [18] Groot PC van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Ther Adv Psychopharmacol 2021; 11: 20451253211039327. PMC8404667 34471516 sourceExperimental — accuracy not yet measured
The Results report lower self-rated withdrawal severity with tapering strips than during previous attempts without them (median 3 versus 6). The Discussion describes three retrospective cohort studies, not trials. These findings suggest less severe withdrawal, but do not establish a reduced incidence of withdrawal symptoms. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“and of these, 4 (19%) included a specific statement on the risk of misinterpreting withdrawal symptoms as depressive relapse, stating that withdrawal symptoms may ‘mimic’, 48 ‘be misdiagnosed as’, 2 ‘mistaken for’ 28 or ‘be hard to distinguish from’ 36 relapse of depressive symptoms.”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Results > Mention of potential benefits and harms associated with tapering and discontinuing antidepressants
What the sources say
- Supportedcites [48] American Academy of Child & Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46: 1503– 1526. 18049300 source
In Recommendation 7 (page unavailable), the source explicitly warns that withdrawal symptoms after abrupt antidepressant discontinuation may mimic depressive relapse or recurrence. The “4 (19%)” figure describes the citing authors’ count of sources, not a finding attributed to this practice parameter. (LLM, conf=0.93)
- Supportedcites [2] Cleare A Pariante CM Young AH, et al Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29: 459– 525. 25969470 source
The guideline’s discussion of stopping antidepressant treatment says discontinuation symptoms can include depressive symptoms and may be misdiagnosed as relapse. This supports the point attributed to this guideline; the count of 4 (19%) is the citing authors’ own tally, not a claim attributed to this source. (LLM, conf=0.91)
- Not checked yetcites [28] American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, DC: American Psychiatric Association, 2010.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
69 more claims · 4 with their cited sources checked
Create a free account to see all 106 claims and to verify the 42 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“National guidelines on tapering of antidepressant and other psychotropic medications, if they exist at all, typically are based on ‘expert opinion’, excluding user knowledge and lived experience, and not very helpful when it comes to the actual process of tapering the medication.1,6,13”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Abstract > Results:
“but none provided guidance on dose reductions, how to distinguish withdrawal symptoms from relapse or how to manage withdrawal symptoms.”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Results > Guidance on duration of tapering period and specific tapering regimen
“Only two (10%) of the CPGs alluded to some form of guidance based on a specific dose-reduction regimen.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Abstract > Results:
“but none provided guidance on dose reductions, how to distinguish withdrawal symptoms from relapse or how to manage withdrawal symptoms.”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Results > Guidance on actions if withdrawal symptoms emerge
“Some form of guidance on how to manage withdrawal symptoms was mentioned in five (24%) of the CPGs.1,2,28,36,39”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > Results > AGREE II quality assessment
“| NZGG + MoH (NZ) 29 | 78 | 47 | 24 | 25 | 17 | 71 | 25 |”
§ Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review > References
“29. American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three cohorts. Washington, DC: American Psychological Association, 2019.”
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 1×
“Mean (SD) 62 (20) 42 (23) 27 (12) 21 (10) 6 (8) 30 (22) 17 (8)”
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514020020010401 · Cited by 1,544
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Research works printed but not linked: 3
- Van Leeuwen E, 2021, Cochrane Database Syst Rev, 4
- American Psychological Association (APA), 2019, Clinical practice guideline for the treatment of depression across three cohorts
- National Institute for Health and Care Excellence (NICE), 2012, Depression: evidence update April 2012: a summary of selected new evidence relevant to NICE clinical guideline 90 ‘The treatment and management of depression in adults’ (2009)
Cited by
Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis
Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00133-0 · Cited by 106
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 104
“This is further complicated by the fact that the current clinical practice guidelines do not offer any guidance on dose adjustments, and how to differentiate and/or manage the withdrawal and relapse symptoms [221].”
BackgroundIncidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Read, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30
Outcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22
Metadata
- Authors
- Sørensen, A., Juhl Jørgensen, K., & Munkholm, K.
- Affiliations
- Copenhagen University Hospital (DK)
- Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- University of Southern Denmark (DK)
- Corresponding author
- Sørensen, Anders
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 12
- Pages
- 20451253211067656-20451253211067656
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC8841913
- OpenAlex
- W4211248784
- Semantic Scholar
- 171edd8b07cafafb772fd96329c63050cc52d638
- Cited by
- 52
- References
- 44
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 4
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant tapering, antidepressant discontinuation, depression, guideline quality, antidepressant withdrawal symptoms, relapse, dose reduction, treatment algorithm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. https://app.cochat.ai/papers/10.1177/20451253211067656
- The paper
- Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022). Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253211067656
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

